Juvenile Idiopathic Arthritis

Immunology·MeSH: Arthritis, Juvenile

Prevalence

75.0 / 100K

16 drugs in development·12 companies·5 clinical trials

Drug Pipeline by Phase

Approved(6)

Phase 3(6)

Drug	Company
Abatacept	ENANTA PHARMACEUTICALS INC (ENTA)
Abatacept	Crinetics Pharmaceuticals, Inc. (CRNX)
Abatacept	Cidara Therapeutics, Inc. (CDTX)
Tocilizumab	ELI LILLY & Co (LLY)
Tocilizumab	Cidara Therapeutics, Inc. (CDTX)
Tocilizumab	AbbVie Inc. (ABBV)

Phase 2(3)

Drug	Company
Kevzara	REGENERON PHARMACEUTICALS, INC. (REGN)
sarilumab sar153191	Sanofi (SNY)
sarilumab sar153191	Sanofi (SNY)

Phase 4(1)

Drug	Company
Recombinant Granulocyte Colony-Stimulating Factor	Cidara Therapeutics, Inc. (CDTX)

BioSniper tracks 16 drugs in development for Juvenile Idiopathic Arthritis across 12 companies.

There are 5 clinical trials targeting Juvenile Idiopathic Arthritis tracked by BioSniper.

The estimated prevalence of Juvenile Idiopathic Arthritis is approximately 75.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.